27 April 2021 | News
Under the terms of the agreement, I2Cure future products would be incubated at IIT-Kanpur
Image Credit: shutterstock.com
The Indian Institute of Technology-Kanpur (IIT-K) has collaborated with I2Cure (P) Ltd, a ‘Make in India for the world’ biotech company for all future research on molecular iodine-based products that would be undertaken by the Biological Sciences & Bioengineering wing of IIT-K.
I2Cure is the first biotechnology company in the world to produce molecular iodine-based i2cure BioShield’, which is a broad-spectrum antimicrobial with proven efficacy of 99.999 per cent against SARS-CoV-2.
Under the terms of the agreement, I2Cure future products would be incubated at IIT-Kanpur. The relationship would be of the equity partners, and validations of Dr Jack Kessler's global research would be done for Indian conditions at IIT-K.
IIT-K would also work with I2Cure to develop new ‘Made in India' products for global markets, especially in tackling long-term problems in the space of human preventive health, veterinary science (FMD, Bovine mastitis, dermatitis), and agri products.
Stating on this momentous occasion, Anil Kejriwal, Founder, Chairman, I2Cure shared, “We would jointly be happy to contribute towards the vision of the Prime Minister of India to double agricultural income as well as become a $5 trillion economy.
Adding to it, (Prof) Dr Ashok Kumar, Biological Sciences & Bioengineering at IIT Kanpur (BSBE), added, “We’re excited about the prospects of IIT-K researched and curated solutions getting global attention.”